CHCWM – Cancer & Hematology Centers of West Michigan

R7075-ONC-1933 (Regeneron)

R7075-ONC-1933 (Regeneron)

Description:  A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid Tumors


Mechanism of Action:  REGN 7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in combination with PD1 inhibitor Cemiplimab

Target Patient Population:  All Solid Tumors. 

Study Design:  Drug is administered IV every 3 weeks.  First patient in each cohort will be inpatient for observation for either 24 or 48 hours.